See which workplaces made this year's list.

2025_GPTW_BiotechnologyPharmaceuticals_Large_Merck_US1__685d500b023fa8a02634231b_1

Employees say:&nbsp;"Senior leadership at Merck is committed to establishing a healthy work environment, and many mid-level managers set a positive example. I believe most Merck employees genuinely strive to make a meaningful impact, both within the work environment and in patient care. A good example is the various mentorship programs I have attended. Despite mentoring me being outside of their job responsibilities and not accounted for in their annual performance reviews, all my mentors have done their best to support me and provide constructive feedback."

Best Large Workplaces in Biotechnology and Pharmaceuticals

The corporations on our annual list of the world's 500 largest companies combined to generate $41.7 trillion in revenue over the past year.

Fortune Global 500

Fortune partnered with Great Place to Work to analyze survey feedback representing nearly 145,000 U.S. employees.

Best Workplaces_New York_Large_2025-Merck_US1__67fd6364bb07cc513ab900de_2

Employees say:"Merck is outstanding at seeing the employee as a "whole person," as a valuable resource to the company and its patients. Over the past several years, I have seen how the company has put concerted effort into ensuring that employees take time away, care for themselves, care for their families, etc. To get the best out of employees, the employees need to BE at their best. And I certainly appreciate how Merck has pivoted and built that flexibility into the rhythms, and now expectations, of employment. It truly is a great place to work. Thank you!"

35 Best Large Workplaces in New York

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

Fortune 500

The top companies on our list have one thing in common: Staff largely trust leadership to see them as well-rounded people and reward them for a job well done.

Employees say: "I feel this company really invests in their people. I started out 25 years ago on a temporary assignment that was to last four days. As long as you have the drive and determination, your career at this company can make an impact and can grow significantly. They provide many tools and opportunities, but it is up to the employee to leverage them. I have a disabled husband who I have to take care of financially and physically, and this company has always been flexible and supportive, which allows me to maintain a great work-life balance and still efficiently get work done. They also support innovation, and I feel new ideas are encouraged and I have seen impact of change initiatives, by either myself, or that my team have brought up."

Fortune 100 Best Companies to Work For

Leaders in all industries rely more than ever on Big Tech—and appreciate the giants that deliver, at scale, without drama.

World's Most Admired Companies

Employees say:"This is more than a company, it is a huge family! Each person, regardless of their role, education, or experience is treated equally importantly. Since our first national meeting, I have repeatedly been acknowledged and never felt unimportant. This work environment is exceptional and each of us strives to work harder and more efficient as we feel appreciated and supported."

Best Large Workplaces for Parents

GPTW_Parents_Large_2024-Merck_US1__20240918135500_1.jpg

Employees say:"Merck is outstanding at seeing the employee as a "whole person," as a valuable resource to the company and its patients. Over the past several years, I have seen how the Company has put concerted effort into ensuring that employees take time away, care for themselves, care for their families, etc. To get the best out of employees, the employees need to BE at their best. And I certainly appreciate how Merck has pivoted and built that flexibility into the rhythms. It truly is a great place to work. "

GPTW BioPharma Large 2024-Merck

Employees say:"The culture of support for the Employee Business Resource Groups creates a physical environment of care, community, and collaboration that fosters trust in both the EBRG teams as well as in the DE&amp;I journey within the greater company culture."

The corporations on our annual list posted aggregate revenues of $41 trillion for the second year in a row.

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

Fortune partnered with Great Place to Work to analyze survey feedback representing nearly 140,000 U.S. employees.

GPTW-2024-New-York-Large-Merck

Employees say:"The main thing that drives me is the sense of ethics and always putting patients first, and not profits. This makes me proud to work here and confident that everyone at the company is driven by the same north."

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

Creating a more empathetic workplace looks like staying loyal to workers, emphasizing D&I initiatives, and paying well.

100 Best Companies 2024-Merck

New Jersey–based pharmaceutical company Merck climbed 36 spots from No. 98 on last year’s Best Companies list, with about 75% of the company’s employees worldwide undergoing a pay equity study as of 2021, which grew to 90% in 2022. That 2022 study, by the way, showed that Merck had achieved over 99% pay equity for both women and men and white and non-white employees in the U.S. &nbsp;Merck’s diversity programs have worked to address gender pay disparities and representation of women in the workplace. The company’s board of directors has more gender diversity than the industry norm, consisting of 46% female representation, while women make up 33% of Merck’s executives. Merck’s Women’s Leadership Program and Emerging Women’s Leadership program provide professional development training for women employees.

The 26th edition of the list shows how much esteem Big Tech giants command among other business leaders.

The 25th Fortune World’s Most Admired Companies list suggests that tech giants’ peers respect them as much as ever.

Building a culture of trust and transparency is essential to help everyone thrive, especially in rocky economic times.

100 BEST COMPANIES 2023-Merck

While Merck’s business focus revolves around using science to save lives and improve physical health, the company has made the mental health of its employees a priority as well. 
<ul> 
 	<li>Roughly 4,000 managers have been trained on how to connect their workers with well-being resources and educated on how to respond with compassion toward someone who may be struggling.</li> 
 	<li>Roughly 100 workers have completed Mental Health First Aid training and are available to help colleagues access mental health information and resources. It’s a grassroots project to reduce the stigma and raise awareness of mental health issues.</li> 
 	<li>Lyra, launched in 2021, ensures both employees and their families have quick access to high-quality evidence-based mental health care.</li> 
 	<li>Employees are provided with a membership to relaxation app Calm, as well as a flex day, time off to volunteer, and a generous parental leave program.</li> 
 	<li>“Merck shows that we are people, not just employees, with lives outside of work and honors that and promotes balancing work/home life,” said one worker.</li> 
</ul>

The corporations on our annual list of the world’s largest companies delivered a record $41 trillion in aggregate revenues.

Fortune partnered with Great Place to Work to analyze survey feedback representing nearly 100,000 U.S. employees.

GPTW-New-York-2023-Merck_1000976-5

Employees say: 
 
"The organization operates with integrity on all levels. Merck is mission-driven and highly principled. Management genuinely cares about employees as individuals—promotes work-life balance and health and wellness, and celebrates diversity. My management listens and follows up on issues brought to their attention and consistently works to remove barriers in processes to help support me and my colleagues in my department to be successful in our jobs."

GPTW 2023 best workplaces pharma LARGE

Employees say: 
 
"The people who work here are amazing and inspiring—people push me to better myself and remind me of what is important and why we do what we do!"

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

F500-2023-069-Merck

The pharmaceutical firm that makes commonly used drugs, including HPV vaccine Gardasil, has held strong in its 69th year on the Fortune 500 list. 
<ul> 
 	<li>Merck surpassed expectations in 2022, bringing in $59.3 billion in revenue and $14.5 billion in profit.</li> 
 	<li>In April 2023, Merck announced plans to acquire Prometheus Biosciences for $10.8 billion. It is one of a few deals of its kind, but analysts say it could signal the beginning of a period of intense M&amp;A for biotech companies.</li> 
 	<li>Merck, along with Moderna, is making progress toward a cancer vaccine for melanoma patients. The immunotherapy drug Keytruda, Merck’s top seller, is part of the vaccine and was a strong growth driver.</li> 
 	<li>Sales of the COVID oral antiviral drug Lagevrio reported robust sales in 2022, but the company expects a significant slowdown in 2023.</li> 
</ul>

Just as it dominates our economy, Big Tech now dominates Fortune’s annual ranking of corporate reputation.

WMAC 2022 41 Merck

Aggregate sales hit $37.8 trillion last year—an increase of 19%, the highest annual growth rate in the list’s history.

The companies on this year's list stand out for celebrating innovation, promoting cooperation, and more.

GPTW New York Large 2022-Merck

Employees say: 
 
“The number of available opportunities/modalities for personal and professional development is truly astounding. Additionally, employees have the opportunity to participate in secondments (away from their hired position) of up to 6 months to work in and learn about another functional area/role. To me, this really emphasizes our company's investment in the PERSON.” 
 
Read the Great Place to Work review .

Great-Places-to-Work-in-Biotechnology-Large-2022-Merck_1000976-3

Employees say: 
 
“The company work culture is very inclusive and compassionate. Everyone is very caring and makes new people feel welcome. It's also very easy to move around departments and working groups. They put a great focus on professional development and networking for everyone.”

Fortune's annual list dedicated to the idea that business is uniquely suited to address society’s biggest challenges.

CTW.1122.Merck Gardasil

Merck’s Gardasil is a potent vaccine against HPV, a sexually transmitted disease that can cause cervical cancer. But until recently, cost and production constraints limited its reach. Merck has now committed more than $1 billion to expand capacity, with a focus on underserved countries. Merck more than doubled global supply of Gardasil between 2017 and 2020 and is on track to do so again by 2023.

Change the World

This year’s Fortune 500 marks the 68th running of the list.

F500-2022-071-Merck

Pharmaceutical company Merck fell six spots on the list in its first year with CEO Robert Davis at the helm. But that modest slide masks a successful year in which profits jumped 85%, to $13 billion. Excluding revenue from Organon, the women’s health company whose spinoff was completed in June 2021, Merck’s sales overall increased 17%, including a 20% gain for the company’s hallmark cancer drug Keytruda and a 44% increase in sales for HPV vaccine Gardasil. Merck also registered nearly $1 billion in sales for molnupiravir, an oral antiviral treatment for COVID that received emergency use authorization from the FDA in December 2021.

After a year in which humanity leaned more heavily than ever on tech giants, see which companies topped Fortune's ranking of corporate reputation.

WMAC 2021-37-Merck

Our 2021 list of the 100 best companies to work for, as ranked by their employees. See which companies made the list.

100 Best companies-100-Merck

New to our list this year, this 130-year-old pharma giant has long devoted itself to the mission: “Save and improve lives.” Though Merck shelved its own vaccine development, President Biden announced in March that the company would help produce J&amp;J’s one-shot COVID vaccine. <a href="https://fortune.com/longform/fortune-500-black-ceos-business-history/">When current CEO Ken Frazier departs</a> at the end of June, CFO Robert Davis will take the reins. Employees say that during a difficult year, it meant a lot that Merck managed to increase benefits to employees. That included the addition of “LifeCare” specialists who can provide help in hiring a nanny or search for virtual tutors to support e-learning.The company has “stepped up,” notes an employee.

Total revenue for the world’s biggest companies fell 4.8% to $31.7 trillion this year—the first decline in half a decade.

G500-2021-232-Merck

<span data-sheets-value="{&quot;1&quot;:2,&quot;2&quot;:&quot;Merck spent much of 2020 developing and testing two COVID-19 vaccine candidates but abandoned the projects in January. The company said in March that it would support the manufacturing and supply of Johnson &amp; Johnson’s COVID-19 vaccine instead. Merck’s worldwide sales increased 2% to $48 billion last year, led by a 30% increase in revenue ($14.4 billion) from its flagship cancer drug Keytruda. Despite the sales growth, Merck saw a 28% decrease in net income in 2020 compared with the prior year. And the numbers in 2021 aren’t exactly flashing green—at least so far: First-quarter sales were flat, and profit declined because of the continuing effects of the pandemic as well as increased competitive pressures for key Merck products. One more challenge for the venerable drugmaker: In June, longtime CEO Ken Frazier steps down after a stellar decade-long run leading the company. He will hand the reins to CFO Robert Davis.&quot;}" data-sheets-userformat="{&quot;2&quot;:14721,&quot;3&quot;:{&quot;1&quot;:0},&quot;10&quot;:2,&quot;11&quot;:4,&quot;14&quot;:{&quot;1&quot;:2,&quot;2&quot;:0},&quot;15&quot;:&quot;Calibri&quot;,&quot;16&quot;:11}">Merck spent much of 2020 developing and testing two COVID-19 vaccine candidates but abandoned the projects in January. The company said in March that it would support the manufacturing and supply of Johnson &amp; Johnson’s COVID-19 vaccine instead. Merck’s worldwide sales increased 2% to $48 billion last year, led by a 30% increase in revenue ($14.4 billion) from its flagship cancer drug Keytruda. Despite the sales growth, Merck saw a 28% decrease in net income in 2020 compared with the prior year. And the numbers in 2021 aren’t exactly flashing green—at least so far: First-quarter sales were flat, and profit declined because of the continuing effects of the pandemic as well as increased competitive pressures for key Merck products. One more challenge for the venerable drugmaker: In June, longtime CEO Ken Frazier steps down after a stellar decade-long run leading the company. He will hand the reins to CFO Robert Davis.

These companies foster supportive cultures, where employees find opportunities for growth with help from their colleagues.

Best Large Workplaces New York 2021-Merck

Employees say: 
 
“Sense of approachability to direct management and genuine concern they show for both work and family life. The encouragement to learn and develop talents and abilities is a consistent focus.”

The best U.S. biotechnology and pharmaceutical companies, as ranked by their employees in the past year.

Best Workplaces Biotech Pharma 2021-Merck & Co

Employees say:  
 
“Benefits increased this year in response to the pandemic and I feel incredibly supported - child care, elder care, mental health support and more.” 
 
Read Great Place to Work review .

This year’s Fortune 500 marks the 67th running of the list.

F500-2021-65-Merck

We surveyed tens of thousands of employees to create this list of millennials’ favorite workplaces.

Best Large Workplaces Millennials 2021-Merck

Employees say: 
 
“I appreciate the co-learning attitude within this company. Even though I might be younger and newer, I have the ability to make an impact and have a voice within the group.”

100 Best Large Workplaces for Millennials

For an astounding 13th straight year, Apple claims the top spot in Fortune’s annual ranking of corporate reputation, based on a survey of almost 3,800 executives, directors, and analysts.

This year's Fortune Global 500 generated $33.3 trillion in revenues and $2.1 trillion in profits.

G500-Featured Image-Logo-2020

The pharma giant had a banner year in 2019, climbing 29 slots on the Global 500. Revenue rose almost 11%, to $46.8 billion, while profits leaped 58%, to $9.8 billion. Blockbuster cancer drug Keytruda, as well as an expanded line of animal medicines, have helped power Merck’s growth—though its share price has not seen as much of a lift as some competitors'. In the race to find a vaccine for COVID-19, Merck has adopted a slow pace compared to others in the industry. Rather than tout the company’s progress, CEO Kenneth Frazier has instead criticized industry “hype” and has warned that the process for developing an effective vaccine could take years

This year's Fortune 500 marks the 66th running of the list.

F500-2020-069-Merck

The pharma giant had a banner year in 2019, climbing seven slots on the Fortune 500. Revenue rose almost 11%, to $46.8 billion, while profits leaped 58%, to $9.8 billion. Blockbuster cancer drug Keytruda, as well as an expanded line of animal medicines, have helped power Merck’s growth—though its share price has not seen as much of a lift as some competitors'. More recently, Merck has been notably quiet in medical chatter about the novel coronavirus. But executives on a late April earnings call announced that the company has teams scanning its portfolio of antiviral candidates and vaccine assets for potential treatments.

As we face unprecedented collective challenges, cooperation has become a business superpower.

53.CTW20.Merck

Merck has doubled down on “impact” investing—taking stakes in smaller companies that aim to generate a measurable social good. Its portfolio currently commits about $39 million to entities working on projects including diagnostics, drug and vaccine R&amp;D, and health infrastructure. It’s a future play with present benefits: Merck estimates more than 9 million people benefited from its impact portfolio in 2019.

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune Global 500 generated $27.7 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 65th running of the list.

Here are the World's Most Admired Companies for 2018 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 64th running of the list.

Here’s our look at 57 companies that do well by doing good.

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 63rd running of the list.

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune Global 500 generated $27.6 trillion in revenues and $1.5 trillion in profits.

This year's Fortune 500 marks the 62nd running of the list.

Business insiders have spoken: Asked which companies they most admire, more than 4,100 executives, directors, and analysts chose these top 50 All-Stars.

The world's 500 largest companies generated $31.2 trillion in revenues and $1.7 trillion in profits in 2014. Together, this year's Fortune Global 500 employ 65 million people worldwide and are represented by 36 countries.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Global business is back. After limping through a worldwide financial crisis and economic slowdown, the 500 largest companies ranked by revenues shattered all sorts of performance records in 2013: They racked up combined revenues of $31.1 trillion, up 2.5% from 2012, and profits soared 27% to nearly $2 trillion. China’s 95 companies (up from 89 last year) posted $5.8 trillion in revenues. The U.S. has four fewer companies on the list than last year but remains (for now) the country leader, with 128 corporations on the list—including No. 1 Wal-Mart Stores—reporting $8.6 trillion in revenues. 

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Change The World

Impact Segment

Sector

Best Workplaces For Parents

Founded

Sites

Industry Vertical

Best Companies

Rank last year

Years on list

U.S. employees

U.S. job openings

Year founded

Benefits

Subsidized childcare

Compressed work weeks

Option to work remotely

Minimum requirement in-office attendance (days per week)

Mental health coverage

Free mental health sessions (per year)

Free backup childcare time off (days)

Maximum $ amount covered for fertility services

Fully paid maternal leave (days)

Fully paid paternal leave (days)

Fully paid adoptive leave (days)

Maternal leave in addition to regular time off (days)

Paid days off for volunteering

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Best Workplaces In New York

Best Workplaces In Biopharma

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

New Jersey–based Merck was founded in 1891 as the American affiliate of a German parent. Today, as a stand-alone company, it is one of the world’s biggest pharmas by revenue. It has produced numerous blockbuster medications, including the cancer treatment branded as Keytruda, which was the world’s bestselling drug in 2023, earning Merck $25 billion that year. Other high-profile medications have included diabetes treatments and anti-HIV drugs. Merck produces vaccines and has a large animal medicine business as well as a services segment whose offerings include analytics and clinical services.

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Merck (U.S.) (MRK): Company Profile, Stock Price, News, Rankings

legacy

Merck (U.S.)

merck (u.s.)

Thank you for standing by. Welcome to the Burke and Company Q4 Sales and Earnings Conference Call. At this time, all participants are in a listen only mode until the question and answer session of today's conference. This call is being recorded. If you have any objections, you may disconnect at this time.

I would now like to turn the call over to Mr. Peter Dannenbaum, Senior Vice President, Investor Relations. Sir, you may begin.

Thank you, Shirley, and good morning, everyone. Welcome to Merck's Q4 2024 Conference Call. Speaking on today's call will be Rob Davis, Chairman and Chief Executive Officer Caroline Litchfield, Chief Financial Officer and Doctor. Dean Lee, President of Merck Research Labs. Before we get started, I'd like to point out that we have items in our GAAP results such as acquisition related charges, restructuring costs and certain other items that we have excluded from our non GAAP results.

There is a reconciliation in our press release. I will also remind you that some of the statements that we make today may be considered forward looking statements within the meaning of the Safe Harbor provision of the U. S. Private Securities Litigation Reform Act of 1995. Such statements are made based on the current beliefs of Merck's management and are subject to significant risks and uncertainties.

If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the forward looking statements. Our SEC filings, including Item 1A in the 2023 10 ks identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any of our forward looking statements made this morning. Merck undertakes no obligation to publicly update any forward looking statements. During today's call, a slide presentation will accompany our speakers' prepared remarks. These slides, along with the earnings release, today's prepared remarks and our SEC filings are all posted to the Investor Relations section of Merck's website.

With that, I'd like to turn the call over to Rob.

Thanks, Peter. Good morning and thank you for joining today's call. 2024 was another year of significant advancement across our company and I'm proud of the continued progress we're making in developing and delivering transformative medicines and vaccines to help save and improve lives around the world. We are impacting patients on a global scale. In fact, in 2024, we reached nearly half a 1000000000 people with our medicines and vaccines, including through donations.

We remain focused on the pursuit of breakthrough science and innovation as the source of sustainable long term value creation for patients and shareholders. We're continuing to execute on our strategic priorities. We're progressing our pipeline, launching important new products that have significant patient benefit and strong commercial potential, advancing key clinical programs in our robust early and late phase pipeline and augmenting our pipeline through promising business development. Our business remains well positioned, thanks to the dedication of our talented global team and I'm more confident than ever in our ability to advance patient care fueling Merck's long term growth potential. Now turning to our results and outlook.

We delivered strong growth in 2024, reflecting demand for our innovative portfolio including for KEYTRUDA, which continues to benefit more patients with cancer globally, the successful launch of LYNRAVIER and strong performance of our Animal Health business. We also saw higher demand and achieved strong sales for GARDASIL outside of China. As we close out 2024 and enter 2025, the market dynamics for GARDASIL in China have remained challenging. Like many other companies, we've seen increased pressure on discretionary consumer spending, including across the vaccine space more broadly and demand for GARDASIL has not recovered to the level we had expected. As a result, overall channel inventory remains elevated at above normal levels.

In light of this and based on further discussions with our commercialization partner, Jirpay, over the past couple of weeks, in particular regarding their most recent financial disclosure and working capital levels, we've made the decision to take a new approach and temporarily pause shipments to China beginning this month and through at least mid year. We believe taking this action now will facilitate a more rapid reduction of inventory and help support the financial position of our important and valued partner. Importantly, we believe China still represents a significant long term opportunity for GARDASIL given the large number of females and now males with our recent approval that are not yet immunized. And we remain both committed and well positioned to maximize this potential for

term. Outside of China, demand for GARDASIL remains robust and we expect strong growth this year and well into the future. Our overall business remains very healthy. In fact, irrespective of the performance of GARDASIL in China, we expect the company to deliver strong growth in the second half of this year as well as in both 2026 and 2027. Longer term, our confidence and our ability to successfully navigate the KEYTRUDA LOE period is unchanged, which is based on the strength of our pipeline, the excitement we have for our ongoing and upcoming launches of innovative new products and the commercial opportunity they represent.

Next, I'd like to turn to our research efforts. We're making remarkable progress across multiple therapeutic areas in our late phase pipeline. In the Q4, we announced FDA acceptance for our filing of presrevimab, our long acting monoclonal antibody to protect infants from RSV disease and positive top line results from 3 programs including for subcutaneous pembolizumab, for zlotrevir in combination with rivarine in the treatment of HIV and for Winrevir from the ZENITH trial. We also executed value enhancing business development that is both science led and portfolio informed. We licensed promising investigational assets including in oncology with the clinical stage anti PD-one VEGF bispecific antibody from lenova and in cardiometabolic with an oral GLP-one receptor agonist candidate from HanSow.

Merck is anchored today by a robust set of commercial products addressing important medical needs and we're rapidly moving to a future with a much more diversified portfolio. We have amassed an expansive pipeline with tremendous potential to further advance the practice of medicine around the world. You can expect a steady cadence of data readouts in the coming months years leading to potential new launches as we seek to bring much needed innovation to patients. In fact, we have 20 potential new growth drivers, almost all of which have blockbuster opportunity. These include Winrevir and Cabaxiv, our adult pneumococcal conjugate vaccine, which is now launching in the U.

S. As well as many innovative assets currently in Phase 3 development. Over the past 3 years, we have nearly tripled the number of assets in late phase development across a broad range of therapeutic areas and modalities. Based on the significant progress, we see over $50,000,000,000 of potential revenue opportunity from these programs. We are positioned for long term leadership in oncology as we continue to diversify and deepen our pipeline.

We are excited about cardiometabolic as a future area of growth, including with our oral PCSK9 inhibitor program where we have important Phase 3 readouts this year. In immunology, HIV and ophthalmology, we have opportunities to bring forward 1st in class and or best in class blockbuster medicines. Further, we expect to benefit from promising programs in our infectious disease and vaccines pipeline, strong growth in our Animal Health business and many early phase programs that will enter Phase 2 over the next few years. And we remain well positioned to pursue additional science driven value creating business development. In summary, I have increased confidence in our long term future.

While the rapid change in the Chinese market for GARDASIL has caused a short term headwind for our company, our overall business is healthy and growing. We remain strongly positioned to successfully navigate the KEYTRUDA LOE period as we continue to deliver on our purpose of saving and improving lives. I want to again recognize the commitment and efforts of our global teams. Together, we remain focused on delivering and sustaining value for patients, shareholders and for all of our stakeholders today and well into the future. With that, I'll turn the call over to Caroline.

Thank you, Rob. Good morning. As Rob noted, we had another year of strong growth, reflecting continued robust demand for our innovative portfolio and demonstrating the importance of our products to the patients we serve. Growth was driven by oncology, animal health and new product launches, which more than offset the Gardasil headwinds in China. These results demonstrate the strength of our business and give us confidence in our outlook.

Our commercial and operational execution enables us to deliver value in the short term, while we invest in new innovations and deliver our pipeline for the long term. Now turning to our 4th quarter results. Total company revenues were $15,600,000,000 an increase of 7% or 9% excluding the impact of foreign exchange. The following revenue comments will be on an ex exchange basis. Our human health business sustained its momentum with sales increasing 8%, driven primarily by oncology.

Our animal health business also delivered strong performance with sales growth of 13%. Turning to the performance of our key brands. In oncology, sales of KEYTRUDA grew 21% to $7,800,000,000 driven by continued robust global demand from metastatic indications and increased uptake from earlier stage cancers. In the U. S, KEYTRUDA grew across all key tumor types.

In metastatic disease, we saw increased uptake for KEYTRUDA in combination with PADCEF in first line, locally advanced urothelial cancer, supported by the strong results from KEYNOTE-eight thirty nine, as well as KEYTRUDA in combination with chemotherapy in first line endometrial cancer based on the compelling data from KEYNOTE-eight sixty eight. In the earlier stage setting, growth was driven by increased use in resectable non small cell lung cancer as well as triple negative breast cancer. Outside the U. S, growth was driven by increased uptake in earlier stage cancers, including high risk early stage triple negative breast cancer, as well as continued demand in metastatic disease. Inflation related price increases, consistent with market practice in Argentina, also contributed to growth.

Our broader oncology portfolio achieved strong growth, including Wellireg, with sales more than doubling to $160,000,000 driven by increased uptake in certain patients with previously treated advanced renal cell carcinoma in the U. S. In vaccines, GARDASIL sales were $1,600,000,000 a decrease of 18% due to lower demand in China. In the U. S, sales benefited from price and demand, partially offset by CDC purchasing patterns.

Outside the U. S. And China, double digit sales growth was driven by higher overall demand, including the catch up cohort in Japan. In pneumococcal, TAVAXID sales were $50,000,000 driven by demand from the retail pharmacy channel. We have made great progress in achieving the commercial milestones necessary to ensure a successful launch and are well positioned to help protect adults from invasive pneumococcal disease.

Merck (U.S.) (MRK) Q4 2024 Earnings Call Transcript

Company Participants